PA8635101A1 - Nuevos derivados de aminopiridina y su uso como farmacos - Google Patents

Nuevos derivados de aminopiridina y su uso como farmacos

Info

Publication number
PA8635101A1
PA8635101A1 PA20058635101A PA8635101A PA8635101A1 PA 8635101 A1 PA8635101 A1 PA 8635101A1 PA 20058635101 A PA20058635101 A PA 20058635101A PA 8635101 A PA8635101 A PA 8635101A PA 8635101 A1 PA8635101 A1 PA 8635101A1
Authority
PA
Panama
Prior art keywords
sexual
disorder
disorders
compounds
dysfunction
Prior art date
Application number
PA20058635101A
Other languages
English (en)
Inventor
Allerton Charlotte Moira Norfor
Andrew Simon Cook
David Hepworth
Duncan Charles Miller
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8635101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0411891A external-priority patent/GB0411891D0/en
Priority claimed from GB0412463A external-priority patent/GB0412463D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PA8635101A1 publication Critical patent/PA8635101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS DE FÓRMULA (I): QUE SON DE UNA CLASE DE AGONISTAS DE DOPAMINA, MÁS PARTICULARMENTE UNA CLASE DE AGONISTAS QUE SON SELECTIVOS PARA D3 SOBRE D2. ESTOS COMPUESTOS SON ÚTILES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE LA DISFUNCIÓN SEXUAL, POR EJEMPLO DE LA DISFUNCIÓN SEXUAL FEMENINA (FSD), EN PARTICULAR EL TRASTORNO DE LA EXCITACIÓN SEXUAL FEMENINA (FSAD), TRASTORNO DEL DESEO SEXUAL HIPOACTIVO (HSDD; FALTA DE INTERÉS EN EL SEXO), TRASTORNO ORGÁSMICO FEMENINO (FOD; INCAPACIDAD PARA ALCANZAR EL ORGASMO); Y LA DISFUNCIÓN SEXUAL MASCULINA, EN PARTICULAR LA DISFUNCIÓN ERÉCTIL MASCULINA (MED). LA DISFUNCIÓN SEXUAL MASCULINA SEGÚN SE REFIERE EN LA PRESENTE MEMORIA SE SUPONE QUE INCLUYE TRASTORNOS EYACULATORIOS TALES COMO EYACULACIÓN PRECOZ, ANORGASMIA (INCAPACIDAD PARA ALCANZAR EL ORGASMO) O TRASTORNOS DEL DESEO TALES COMO EL TRASTORNO DEL DESEO SEXUAL HIPOACTIVO (HSDD; FALTA DE INTERÉS EN EL SEXO). ESTOS COMPUESTOS TAMBIÉN SON ÚTILES PARA TRATAR TRASTORNOS NEUROPSIQUIÁTRICOS Y TRASTORNOS NEURODEGENERATIVOS.
PA20058635101A 2004-05-27 2005-05-26 Nuevos derivados de aminopiridina y su uso como farmacos PA8635101A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0411891A GB0411891D0 (en) 2004-05-27 2004-05-27 New aminopyridine derivatives and their use as pharmaceuticals
GB0412463A GB0412463D0 (en) 2004-06-03 2004-06-03 New aminopyridine derivatives and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
PA8635101A1 true PA8635101A1 (es) 2006-05-16

Family

ID=34970000

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058635101A PA8635101A1 (es) 2004-05-27 2005-05-26 Nuevos derivados de aminopiridina y su uso como farmacos

Country Status (21)

Country Link
EP (1) EP1758862A1 (es)
JP (1) JP4198183B2 (es)
AP (1) AP2006003824A0 (es)
AR (1) AR049548A1 (es)
AU (1) AU2005247699A1 (es)
BR (1) BRPI0511571A (es)
CA (1) CA2567935C (es)
EA (1) EA200601982A1 (es)
EC (1) ECSP067029A (es)
GT (1) GT200500125A (es)
IL (1) IL179314A0 (es)
MA (1) MA28607B1 (es)
MX (1) MXPA06013786A (es)
NL (1) NL1029139C2 (es)
NO (1) NO20065326L (es)
PA (1) PA8635101A1 (es)
PE (1) PE20060366A1 (es)
SV (1) SV2005002129A (es)
TW (1) TW200609216A (es)
UY (1) UY28925A1 (es)
WO (1) WO2005115985A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502509D0 (en) 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
JP5777526B2 (ja) * 2009-02-13 2015-09-09 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 縮合ピリミジン類
ES2552166T3 (es) * 2010-04-12 2015-11-26 Supernus Pharmaceuticals, Inc. Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas
JP6075654B2 (ja) 2011-06-30 2017-02-08 ドナルドソン カンパニー，インコーポレイティド 空気／油分離装置アセンブリ、部品及び方法
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
CN109641871B (zh) 2016-07-20 2021-10-22 诺华股份有限公司 氨基吡啶衍生物及其作为选择性alk-2抑制剂的用途
AU2020270992A1 (en) * 2019-04-12 2021-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
IL293085A (en) 2019-11-22 2022-07-01 Incyte Corp Combined treatment that includes an alk2 inhibitor and a jak2 inhibitor
TW202214239A (zh) 2020-06-16 2022-04-16 美商英塞特公司 用於治療貧血之alk2抑制劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) * 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
RS51442B (en) * 2002-12-10 2011-04-30 Pfizer Inc. MORPHOLINE DERIVATIVES USED AS DOPAMINE AGONISTS IN TREATMENT I.A. SEXUAL DYSFUNCTIONS

Also Published As

Publication number Publication date
JP2008500331A (ja) 2008-01-10
AR049548A1 (es) 2006-08-16
AP2006003824A0 (en) 2006-12-31
UY28925A1 (es) 2005-12-30
ECSP067029A (es) 2006-12-29
NO20065326L (no) 2006-12-19
IL179314A0 (en) 2007-03-08
EA200601982A1 (ru) 2007-04-27
PE20060366A1 (es) 2006-05-15
CA2567935A1 (en) 2005-12-08
AU2005247699A1 (en) 2005-12-08
TW200609216A (en) 2006-03-16
NL1029139A1 (nl) 2005-11-30
JP4198183B2 (ja) 2008-12-17
NL1029139C2 (nl) 2006-06-19
EP1758862A1 (en) 2007-03-07
WO2005115985A1 (en) 2005-12-08
BRPI0511571A (pt) 2008-01-02
GT200500125A (es) 2006-01-10
SV2005002129A (es) 2005-12-13
MXPA06013786A (es) 2007-01-25
CA2567935C (en) 2009-10-27
MA28607B1 (fr) 2007-05-02

Similar Documents

Publication Publication Date Title
PA8635101A1 (es) Nuevos derivados de aminopiridina y su uso como farmacos
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2018000128A1 (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
SV2016005257A (es) Benzimidazol-2-aminas como inhibidores de midh1
DOP2016000140A (es) Inhibidores de syk
MY195437A (en) Methods of Treatment for Cholestatic and Fibrotic Diseases
GT201300055A (es) Formulacion de premezcla de dexmedetomidina
DOP2011000260A (es) Pirimidinas fusionadas
CL2012002905A1 (es) Compuestos derivados de heteroaril-ciclohexil-tetraazabenzo(e)azulenos sustituidos, moduladores del receptor de vasopresina v1a; procedimiento de preparacion; composición farmacéutica; y su uso para la prevención o el tratamiento de la dismenorrea, disfunción sexual masculina o femenina, ansiedad, entre otros.
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
ECSP10010032A (es) derivados de azaciclilisoquinolinona e -isoindolinona como antagonistas de la HISTAMINA-3
CO6300955A2 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina -3
CL2017003133A1 (es) Uso de derivados de bencimidazol para escape ácido nocturno
SV2017005368A (es) [1,2,4] triazolo [4,3-b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CL2020001107A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
SV2008002653A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
ECSP067024A (es) Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos
DOP2005000095A (es) Nuevos derivados de aminopiridina y su uso como farmacos
DOP2005000093A (es) Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos
CO2016005712A1 (es) Composición farmacéutica para la disfunción eréctil de administración transdérmica vía uretral en gotas
AR096322A1 (es) Derivados de pirimidin-4-il)oxi)-1h-indol-1-carboxamida y uso de los mismos
CR20140489A (es) Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t
CU20100045A7 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
CU20100047A7 (es) Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3